Literature DB >> 22945211

Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls.

Alzbeta Kubistova1, Jiri Horacek, Tomas Novak.   

Abstract

BACKGROUND: Inflammatory immune processes have been clearly implicated in the etiopathology of schizophrenia. There are, however, only limited data dealing with immune parameters in the first episode patients with schizophrenia and the course of these parameters during treatment. SUBJECTS AND METHODS: The presented study compared plasma levels of interleukin (IL)-6, IL-8, IL-10 and TNF-alpha in 25 patients with the first episode of schizophrenia with the minimal exposition of antipsychotics before and after treatment and with age and sex matched group of healthy volunteers. Changes in plasma cytokine levels were investigated after 4 weeks of treatment in relationship with the therapeutic outcome.
RESULTS: Our results show significantly increased plasma levels of IL-6 (p≤0.001) and TNF-alpha (p≤0.001) in patients at the admission in comparison with healthy volunteers. After 4 weeks of the treatment the PANSS score decreased (p≤0.001), concurrently the plasma level of IL-6 decreased and TNF-alpha did not show any decrease after treatment. The patients' posttreatment and healthy control group comparison showed higher plasma levels of TNF-alpha (p=0.008) and marginally elevated plasma level of IL-6 (p=0.046) in the posttreatment group. Plasma levels of IL-8 and IL-10 did not show any significant differences.
CONCLUSIONS: Our study validated the presence of the proinflammatory state in the first episode of schizophrenia. IL-6 may be considered as a state marker for acute exacerbations and TNF-alpha may be a trait marker of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22945211

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  14 in total

1.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

2.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Authors:  Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-17       Impact factor: 4.105

Review 3.  Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders.

Authors:  Elizabeth K Nousen; Juliana G Franco; Elinor L Sullivan
Journal:  Neuroendocrinology       Date:  2013-09-21       Impact factor: 4.914

Review 4.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Authors:  Guillaume Fond; Marc-Antoine d'Albis; Stéphane Jamain; Ryad Tamouza; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Iris E Sommer; Inge Winter-van Rossum; Shitij Kapur; René S Kahn; Dan Rujescu; Marion Leboyer
Journal:  Schizophr Bull       Date:  2015-03-10       Impact factor: 9.306

5.  Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.

Authors:  Cristiano Noto; Vanessa Kiyomi Ota; Eduardo S Gouvea; Lucas B Rizzo; Leticia M N Spindola; Pedro H S Honda; Quirino Cordeiro; Sintia Iole Belangero; Rodrigo Affonseca Bressan; Ary Gadelha; Michael Maes; Elisa Brietzke
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

6.  Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia.

Authors:  Saeed Kadasah; Misbahul Arfin; Sadaf Rizvi; Mohammed Al-Asmari; Abdulrahman Al-Asmari
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-12       Impact factor: 2.570

7.  The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia.

Authors:  Kayla A Chase; Jackson J Cone; Cherise Rosen; Rajiv P Sharma
Journal:  BMC Psychiatry       Date:  2016-05-20       Impact factor: 3.630

Review 8.  Inflammation, Stress Response, and Redox Dysregulation Biomarkers: Clinical Outcomes and Pharmacological Implications for Psychosis.

Authors:  Stefania Schiavone; Luigia Trabace
Journal:  Front Psychiatry       Date:  2017-10-25       Impact factor: 4.157

Review 9.  Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models.

Authors:  Toby Pillinger; Enrico D'Ambrosio; Robert McCutcheon; Oliver D Howes
Journal:  Mol Psychiatry       Date:  2018-05-09       Impact factor: 15.992

10.  Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis.

Authors:  Bruno Romeo; Marine Brunet-Lecomte; Catherine Martelli; Amine Benyamina
Journal:  Int J Neuropsychopharmacol       Date:  2018-09-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.